The current coronavirus pandemic is an ongoing global health crisis due to COVID-19,
caused by severe acute respiratory syndrome coronavirus 2. Although COVID-19 leads to …

Hepatitis B virus (HBV) infection causes chronic hepatitis and has long term complications.
Individuals ever infected with HBV are at risk of viral reactivation under certain …

Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several
cancers. While these immunotherapies have improved patient outcomes in many clinical …

The introduction and broad use of new immunosuppressive agents, including biologic
agents and JAK inhibitors, have revolutionised treatment of inflammatory bowel disease …

The 2020 annual meeting for IOIBD was scheduled to occur in March, but was cancelled
owing to the emergence of COVID-19. Given how this disease might affect patients with IBD …

Ulcerative colitis (UC), a relapsing-remitting chronic inflammatory bowel disease (IBD), has
a variable natural course but potentially severe disease course. Since the development of …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has a direct
impact on the gastrointestinal system, as up to 50% of fecal samples from coronavirus …

Introduction: Efficacy and safety are key aspects when choosing therapies for patients with
inflammatory bowel diseases (IBD). While several randomized trials and indirect …

Background One quarter of the world's population has latent tuberculosis infection (LTBI).
Systemic immunosuppression is a risk factor for LTBI reactivation and the development of …

Abstract Background and Aims Vedolizumab is a gut-selective antibody to α 4 β 7 integrin,
approved to treat moderate-to-severe ulcerative colitis and Crohn's disease in adults …